丹参酮ⅡA治疗缺血性脑卒中的疗效及经济学评价  

The efficacies of tanshinone ⅡA for the treatment of ischemic cerebral stroke and its economic evaluation

作　　者：王荣[1] 孙建田 贺云波[1] 

机构地区：[1]安徽省宿州市第一人民医院神经内科,234000

出　　处：《中华神经医学杂志》2007年第9期967-969,共3页Chinese Journal of Neuromedicine

摘　　要：目的探讨丹参酮ⅡA治疗缺血性脑卒中的疗效及其成本—效果比,为临床合理用药提供经济学依据。方法收集符合纳入标准的155名缺血性脑卒中患者,按随机数字表随机分为丹参酮ⅡA组(77例)和尼莫地平组(78例),进行同期盲法试验3周,观察治疗前后缺血性脑卒中患者的症状、体征和颅脑CT检查结果的变化,并计算治疗的总成本,评价成本—效果比。结果丹参酮ⅡA组和尼莫地平组患者症状和体征及颅脑CT检查均有明显改善,总有效率分别为74.02%和71.79%,两组疗效比较无统计学意义。两组治疗后神经功能缺损评分均显著降低(P<0.05),且丹参酮ⅡA组显著低于尼莫地平组(P<0.05)。丹参酮ⅡA组不良反应发生率为9.09%,显著低于尼莫地平组26.92%(P<0.05)。丹参酮ⅡA组治疗成本—效果比2 490.38元(总成本184 338元/总有效率74.02%),低于尼莫地平组8 259.65元(总成本592 960.56元/总有效率71.79%)。结论丹参酮ⅡA治疗缺血性脑卒中的效果与尼莫地平近期疗效相当,不良反应低,有经济学价值。Objective To investigate the efficacies of tanshinone IIA for the treatment of ischemic cerebral stroke and its cost-effectiveness ratio （CER）, providing economic basis for the rational use of clinical drugs. Methods A total of 155 patients with ischemic cerebral stroke, who were considered to be suitable for inclusion, were enrolled and allocated into the tanshinone IIA group （n=77） and nimodipine group （n=78） by the table of random digits, at the same with the 3-week blind test. Changes in symptoms, signs and the results of brain CT scan of the patients were observed before and after treatment; the total cost for the treatment was calculated and the cost-effectiveness was evaluated. Results The symptoms, signs and the result of brain CT scan of the patients were all changed in the tanshinone IIA and nimodipine groups, with the respective total effective rates of 74.02% and 71.79%; comparisons between efficacies of the two groups had no statistical significance. The nerve function deficit scores of the two groups remarkably decreased after treatment （P〈0.05）, and the score of the tanshinone IIA group was evidently lower than that of the nimodipine group （P〈0.05）. The occurrence rate of reverse effects was 9.09% in the tanshinone IIA group, which was evidently lower than that of 26.92% in the nimodipine group （P〈0.05）. The CER of the tanshinone IIA group was 2 490.38 Yuan （total cost RMB 184 338 Yuan/total effective rate 74.02%）, which was lower than that of 8 259.65 Yuan of the nimodipine group （total cost RMB 592 960.56 Yuan/total effective rate 71.79%）. Conclusion The short term efficacy of tanshinone IIA in treating with ischemic cerebral stroke is equivalent to that of nimodipine, with low occurrence rate of reverse effects, so it has economic value.

关 键 词：丹参酮IIA 尼莫地平 缺血性脑卒中 成本-效果分析 

分 类 号：R743.33[医药卫生—神经病学与精神病学]